HRSA responds to AHA outreach regarding Johnson & Johnson’s unilateral imposition of 340B rebate model 

Aug 23, 2024 - 02:34 PM
340B pic

Johnson & Johnson announced Aug. 23 that it would be fundamentally changing the way it makes 340B pricing available for two of its most popular products, Stelara and Xarelto. Starting Oct. 15, J&J will require all disproportionate share hospitals participating in the 340B Drug Pricing Program to purchase these drugs at full price and submit data to J&J. Upon verification of the drug’s 340B status, DSHs would receive a rebate for the discounted 340B price.

Last week, the AHA contacted the Health Resources and Services Administration for more information as soon as it was made aware that J&J was considering these actions. HRSA notified the AHA today that it has informed J&J that its rebate model is inconsistent with the 340B statute and that this model has not been approved by the Secretary of the Department of Health and Human Services. HRSA further informed the AHA that it will take appropriate action as warranted.
 

Related News Articles

Headline
District court rules in favor of Tennessee’s 340B contract pharmacy law
The U.S. District Court for the Middle District of Tennessee June 30 denied a motion for a preliminary injunction by AbbVie in its lawsuit against the state’s…
Headline
AHA files amicus brief in second lawsuit challenging Tennessee’s 340B contract pharmacy law 
The AHA June 27 filed an amicus brief in the U.S. District Court for the Middle District of Tennessee that defends the state’s 340B contract pharmacy law…
Chairperson's File
Chair File: Leadership Dialogue — Legal Advocacy to Protect Hospitals With AHA General Counsel Chad Golder
Public
Advocacy is a core part of the work of the AHA, protecting and sustaining what hospitals and health systems need to truly care for our communities. We often…
Headline
Judge rules against J&J, for HHS and 340B hospitals in rebate model case
A U.S. District Court for the District of Columbia judge June 27 ruled against Johnson & Johnson and sided with the Department of Health and Human Services…
Headline
AHA report: Hospitals are complying with 340B rules, but drug companies are not 
The AHA June 16 released a report showing hospitals that participated in the 340B Drug Pricing Program are not only subject to disproportionately greater…
Chairperson's File
Chair File: The Importance of Legal Advocacy
Public
Advocacy is such an important part of what we do as hospitals and health systems — and what the AHA does on behalf of our field — to help ensure that we get…